Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Hydra Biosciences, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Steven Richard Brunette

Michael Robert Turner

Robert Sibley

Qiang Zhang

Hossein Razavi

Robert Owen Hughes

Thomas Martin Kirrane, Jr

Lana Louise Smith Keenan

Xiang Li

Asitha Abeywardane

Matt Aaron Tschantz

Bryan Patrick McKibben

Michael David Lawlor

Renee M Zindell

Hidenori Takahashi

Lifen Wu

Rene Marc Lemieux

Erick Richard Roush Young

Michael Jason Burke

Zhaoming Xiong

Craig Andrew Miller

Jin Mi Kim

Shuang Liang

Jennifer A Kowalski

Hui Yu

Joshua Courtney Horan

Delphine Collin

Johanna Bakonyi

Eugene R Hickey

Weimin Liu

Neil Moss

Thierry Bouyssou

Derek Cogan

Christopher Ronald Sarko

Roger John Snow

Xinyuan Edward Wu

Suresh R Kapadia

Ronald John Sorcek

Zhidong Chen

Yunlong Zhang

Daniel Richard Marshall

Donghong Amy Gao

Matthew Russell Netherton

Anil Kumar Padyana

Michael Dennis Lowe

Jiang-Ping Wu

Alexander Heim-Riether

Sonia Rodriguez

Simon Surprenant

Joerg Bentzien

René Marc Lemieux

Johanna Csengery

Anjan Saha

Antonio J M Barbosa

Steven John Taylor

Chuk Chui Man

Qing Zhang

Antonio J M Barbosa, Jr

Jianwen Cui

Yang Yu

Michael J Burke

Antonio Jose Del Moral Barbosa, Jr

Lana Louise Smith-Keenan

John Broadwater

Rene′ Marc Lemieux

Paul Nicklin

John Alan Broadwater

Thomas Martin Kirrane

Joerg Martin Bentzien

Bryan Mckibben

Michael Jason Bruke

Donghong A Gao

Antonio Jose Del Moral Barbosa

Antonio JM Barbosa

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein Rto R, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Inhibitors of TRPC6

The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR&#x3b3; and the treatment of diseases related to the modulation of ROR&#x3b3;. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Pteridine derivatives as modulators of ROR gamma

The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR&#x3b3; and the treatment of diseases related to the modulation of ROR&#x3b3;. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Compounds as modulators of ROR&#x3b3;

The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene Ahydrolase (LTAH) and treating LTAH related disorders. The present invention also relates to pharmaceutical compositions comprising the aryl pyrazoles of the present invention, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Inhibitors of leukotriene production

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A, A, Land B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTAH) and treating LTAH related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

The present invention relates to compounds of formula (I): wherein Rto R, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Benzodioxane inhibitors of leukotriene production

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

[object Object]

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

Disclosed are novel compounds of formula (I): wherein X, Y, R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-sulfonyl]-azetidine-carboxylic acids, esters and amides which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-azetidine-carboxylic acids, esters and amides

Disclosed are novel compounds of formula (I): wherein R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyridine derivatives useful as inhibitors of PKC-theta

Growing community of inventors

New Milford, CT, United States of America

Steven Richard Brunette